Search Results

You are looking at 71 - 80 of 237 items for :

  • "neoadjuvant chemotherapy" x
Clear All
Full access

Kwang-Yu Chang, Jang-Yang Chang, Joseph Chao and Yun Yen

. Urschel JD Vasan H Blewett CJ . A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer . Am J Surg 2002 ; 183 : 274 – 279 . 24. Ancona E Ruol A

Full access

Interstitial Cystitis-Like Symptoms to Neoadjuvant Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Bladder Pokuri Venkata a MD Sule Norbert b MD, PhD Soofi Yousef b MD Xu Bo b MD, PhD Guru Khurshid c MD George

Full access

, PhD 04 2014 12 12 4 4 502 502 511 511 0120502 10.6004/jnccn.2014.0055 Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer Cercek Andrea a MD Goodman Karyn A

Full access

Tara M. Breslin, Marcy Waldinger and Samuel M. Silver

UMCCC experienced more rapid transition from biopsy to surgery or neoadjuvant chemotherapy, and surgery to adjuvant chemotherapy than those who received a portion of their care outside the center. This finding is not surprising, because EHR and internal

Full access

J. Sybil Biermann, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, James E. Butrynski, David Cheong, Warren Chow, William T. Curry, Deborah A. Frassica, Frank J. Frassica, Kenneth R. Hande, Francis J. Hornicek, Robin L. Jones, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Margaret von Mehren, Mary Anne Bergman and Hema Sundar

functional outcomes. 185 In patients with high-grade osteosarcomas with good histologic response to neoadjuvant chemotherapy, limb-sparing surgery is considered the preferred surgical modality if wide surgical margins could be achieved. 182 , 186 Amputation

Full access

e RN, PhD McGilton Katherine S. a f RN, PhD Alibhai Shabbir M.H. g MD, MSc 10 2017 15 15 10 10 1208 1208 1215 1215 jnccn_15_10_008 10.6004/jnccn.2017.0159 Pathologic Complete Response After Neoadjuvant Chemotherapy and Long

Full access

b PhD 11 2015 13 13 11 11 1366 1366 1374 1374 jnccn0131366 10.6004/jnccn.2015.0165 Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology

Full access

Virginia G. Kaklamani and William J. Gradishar

study, the use of neoadjuvant chemotherapy is considered equivalent to adjuvant chemotherapy as far as long-term efficacy is concerned. Can Response to Preoperative Therapy Predict for Long-Term Outcomes? After 9 years of follow-up in the NSABP B

Full access

Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar and E. Aubrey Thompson

nonamplification by fluorescence in situ hybridization, and a Ki-67 level of 70%. Further staging using a PET/CT scan, bone scan, and brain MRI did not show definite evidence of distant metastatic disease. The patient received neoadjuvant chemotherapy with

Full access

Bishal Gyawali and Saroj Niraula

.gov identifier: NCT01042379 ). The arms consist of one common control arm of standard neoadjuvant chemotherapy with paclitaxel (with an alternate control arm of paclitaxel + trastuzumab or pertuzumab + trastuzumab if HER2-positive) against which other